In addition to immune barriers, molecular incompatibilities between species are predicted to limit pig liver survival in primate xenotransplantation models. Assessment and measurement of synthetic function of genetically modified porcine livers after ex vivo perfusion with human blood have not previously been described. Eight porcine livers from α1,3-galactosyl transferase knockout and human membrane cofactor (GalTKO.hCD46), six livers from GalTKO.hCD46 and N-glycolylneuraminic acid knockout (GalTKO.hCD46.Neu5GcKO), and six livers from GalTKO.hCD46 with humanized decay-accelerating factor (hCD55), endothelial protein C receptor (hEPCR), tissue factor pathway inhibitor (hTFPI), and integrin-associated protein (hCD47) (GalTKO.hCD4 6.hCD55.hEPCR.hTFPI.hCD47) pigs were perfused with human blood under physiologic conditions. Timed blood samples were tested for liver enzymes and for pigspecific albumin production via Western blot. Porcine albumin levels increased with time in all experiments. By densitometry, GalTKO.hCD46.Neu5GcKO livers had the highest albumin levels, measured both as total produced, and when controlled for perfusion duration, compared to GalTKO.hCD46 (P = .068) and GalTKO.hCD46.hCD55.h EPCR.hTFPI.hCD47 livers (P = .04). Porcine livers perfused with human blood demonstrated the synthetic ability to produce albumin in all cases. GalTKO.hCD46.Neu5GcKO pig livers demonstrated the most robust albumin production. This suggests that the Neu5GcKO phenotype provides a protective effect on the graft due to decreased human antibody recognition and graft injury.
The liver plays a central role in all metabolic processes in the human body contributing to plasma protein synthesis, including albumin and clotting factors, detoxification, bile production, and glucose regulation. At any given time, approximately 25% of the liver's energy is devoted to albumin production, with an average of 12 grams of albumin made daily. Serum albumin plays a critical role in homeostatic functions including maintenance of plasma oncotic pressure, regulation of body fluid distribution, and transport of small molecules. 4 The large synthetic burden is unique to the liver and further highlights the importance of functional assessment of liver xenografts. A 2015 review of cross-species hepatocyte transplants, which included studies examining albumin production, highlighted promising results when wild-type pig or human hepatocytes were injected into mice, rats, or monkeys. 5 Specifically, a study by Nagata et al 6 , which transplanted wild-type porcine hepatocytes into the spleens of cynomolgus monkeys treated with immunosuppression, demonstrated porcine albumin production (measured via ELISA) for up to 80 days. However, a more recent experience using genetically modified pig hepatocytes injected into the spleen, kidney, mesenteric lymph nodes, and adipose tissue of baboons showed disappointingly low levels of porcine mRNA and albumin production. 7 One study looking at orthotopic genetically modified pig liver transplants into baboons was able to show evidence for the production of porcine albumin and clotting factors over several days. 8 New genomic editing techniques now allow for multiple targeted genetic modifications in donor animals (pigs). Addressing or eliminating known xeno-antigens as well as complement and coagulation regulation incompatibilities could protect and enhance the function of porcine liver xenografts. Current genetic modifications available in pigs include knockout of α-1,3 galactosyltransferase enzyme (GalTKO), removing the 1,3 αGal epitope from the surface of pig cells, a key step in preventing hyperacute rejection. 9 Further attention to addressing "non-Gal" xeno-antigens has resulted in the production of "triple knockout" pigs, which lack N-glycolylneuraminic acid (Neu5Gc) and β1,4N-acetylgalactosaminyl transferase (β4GalNT2), both surface carbohydrate moieties, in addition to the GalTKO, 10 designed to reduce residual antibody-mediated graft injury. Other modifications are knock-ins of genes encoding human complement regulatory proteins such as CD46 (hCD46, membrane cofactor protein) and CD55
(hCD55, decay-accelerating factor); expression of these complement pathway regulatory proteins actively inhibit complement injury to cells on which anti-pig antibody is bound. 11 Similarly, expression of human endothelial cell protein C receptor (hEPCR) and human tissue factor pathway inhibitor (hTFPI) has been genetically introduced into pigs, intending to inhibit non-physiologic activation of clotting mechanisms that are triggered when pig endothelium is exposed to human blood.
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While some groups have looked at hepatic function in xenotransplant in vivo models, detection of synthetic function such as albumin was inconsistent, and the ability of human blood to support synthetic function of multi-gene modified pig livers ex vivo has not previously been described. Here, we investigate the albumin production capability of several strains of genetically modified pig livers when perfused ex vivo with human blood.
| MATERIALS AND METHODS

| Animals
Twenty transgenic pigs were obtained from Revivicor, Inc. (Blacksburg, VA) with the following genotypes: α1,3-galactosyl transferase knockout and human membrane cofactor (GalTKO.hCD46, "2-gene", n = 8),
GalTKO.hCD46 and N-glycolylneuraminic acid knockout (GalTKO.
hCD46.Neu5GCKO, "3-gene", n = 6), and GalTKO.hCD46 and human decay-accelerating factor (hCD55), endothelial protein C receptor (hEPCR), tissue factor pathway inhibitor (hTFPI), and integrinassociated protein (hCD47) (GalTKO.hCD46.hCD55.hEPCR.hTFPI.
hCD47, "6-gene", n = 6). Expression of all transgenes in the liver was validated by immunohistochemistry (data not shown). All animal protocols were approved by the Institutional Animal Care and Use
Committee at the University of Maryland School of Medicine.
| Liver procurement
Pig liver procurement has been described previously. 
| Blood collection
| Blood additives
Collected human whole blood was diluted 1:1 with blood type com- Table 1 ).
| Liver perfusion
Our liver perfusion system has been previously described. 13 Briefly, blood was placed in a heated reservoir (37°C) and pumped through an oxygenator (Dideco neonatal oxygenator, Sorin Group, Arvada, CO, USA), and the outflow was split and pumped through the hepatic artery and shunted back to the reservoir. Partially oxygenated blood was pumped through the portal vein. Outflow from the liver was returned via the suprahepatic vena cava. Perfusions were terminated when elevated vascular pressures precluded flow or if uncorrectable metabolic derangements were noted. Thus, "survival" was calculated as the time from reperfusion of the liver with human blood to the point of termination as dictated by the above criteria.
| Blood sampling and processing
Blood was collected from the suprahepatic vena cava outflow at timed intervals throughout the perfusion in EDTA vacutainer tubes (Becton Dickinson), supplemented with meclofenamate (10 μg/mL) and benzamidine (1 mM) (Sigma-Aldrich, St. Louis, MO, USA) after the vacuum was broken. The tubes were centrifuged at 1430 g for 15 minutes.
Plasma was stored at −80°C until used. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured via commercial laboratory (Antech, Rockville, MD, USA). 
| Western blotting
| Data analysis
Band intensities were averaged across genotypes at comparable time points. Average intensity was divided by experimental length to control for differing durations of perfusions. All data are presented as mean and standard error of the mean. Two-tailed t tests were used to compare groups with a P value < .05 considered significant. All statistical analyses were carried out with GraphPad Prism software (GraphPad, Inc). When controlling for one experiment in the GalTKO.hCD46 (2-gene) group that had disproportionately high ALT and AST levels for unknown reasons, there was no difference in ALT levels between the three groups. (C) AST levels remained low in the GalTKO.hCD46.hCD55.hEPCR.hTFPI.hCD47 (6-gene) group. AST levels rose to above physiologically normal levels in the GalTKO.hCD46 (2-gene) and GalTKO.hCD46.Neu5GcKO (3-gene) groups with the highest levels seen in the GalTKO.hCD46 group (2-gene). (D) When controlling for one experiment in the GalTKO.hCD46 (2-gene) group that had disproportionately high ALT and AST levels for unknown reasons, the AST levels of the GalTKO.hCD46 (2-gene) and GalTKO.hCD46.Neu5GcKO (3-gene) groups were not significantly different significance compared to the 3-gene group (P = .05) (Figure 1 ). Within each group, survival did not appear to be affected by drug treatment (Table 1) .
| RESULTS
| Graft survival
| Vascular resistance
In all experiments, the perfusion pressures of both the portal vein and hepatic artery were maintained within normal physiologic ranges until approximately 30 minutes prior to termination when resistance in both vessels sharply increased. This pattern of behavior was observed regardless of drug treatment.
| Transaminase levels
ALT levels increased gradually in all experiments. In the 3-gene and 6-gene groups, there was no difference, and ALT levels stayed within normal range (Figure 2A ). ALT levels in the 2-gene group increased more sharply after 2 hours and were higher than the other two groups. However, this was due to one single experiment with high transaminase levels for unknown reasons. Controlling for this experiment, there was no difference in ALT levels between the three groups and all values were within physiologic range ( Figure 2B ). AST levels in the 6-gene group increased gradually and remained within physiologic range. However, AST levels in the 2-gene and 3-gene groups rose sharply to above physiologic normal ranges by 1 hour ( Figure 2C ).
Again, one experiment in the 2-gene group had high transaminase levels for unknown reasons and controlling for this experiment showed AST levels closer to those of the 3-gene group ( Figure 2D ).
| Albumin production
All livers were noted to produce porcine albumin, and albumin levels increased over time in all experiments ( Figure 3A,B) . A human IgG band serving as a loading control was detected in addition to the albumin band in all experimental lanes. There was minimal cross-reactivity with human albumin, and any background signal measured in human control samples was subtracted from the porcine samples. Total albumin produced, as measured by band intensity (I) of final time point samples in all experiments, was divided by the length of perfusion in hours to control for different durations of perfusion. Average albumin production was highest in the 3-gene group (1515 I/h), followed by the 2-gene group (576 I/h), and lowest in the 6-gene group (278 I/h) ( Figure 3C ). The 3-gene group produced significantly more albumin than the 6-gene group (P = .04).
| DISCUSSION
Extending graft survival in xenotransplantation models is a key step experiments. An appropriate IgG loading control band (green) was observed in all experimental lanes. (C) Band intensities were measured by densitometry, and the background signal detected in human control plasma was subtracted from each time point in the same gel. Total albumin detected was then divided by the duration of perfusion to account for different lengths of perfusions and obtain intensity/h units. The GalTKO.hCD46.Neu5GCKO (3-gene) livers had the most robust albumin production xenograft protein production. Ekser et al 8 measured levels of pigspecific proteins produced in baboons who had undergone GalTKO.
hCD46 porcine liver transplants. They were able to demonstrate via
Western blot that over a period of 4-7 days porcine livers produced albumin, fibrinogen, haptoglobin, and plasminogen. They also showed that the levels of multiple coagulation factors increased over time pointing to synthesis by the transplanted liver. These encouraging results prompted us to test whether human blood could support synthetic function in a clinically applicable model. In our study, we showed that transgenic pig livers were able to carry out synthetic metabolism when perfused ex vivo with human blood. Notably, albumin production was detected after a short time period of a few hours in our experiments, showing evidence of immediate graft function. Total albumin detected increased over time in all experiments; however, the actual rate of albumin production decreased over time in the longer experiments. This could reflect an initial robust response to a stress state detected by the liver on reperfusion followed by equilibration to a lower steady state of synthesis over time. We found that the GalTKO.hCD46.
Neu5GCKO livers performed better than the GalTKO.hCD46 livers and postulate that this observation is related to the relative protection of the Neu5GcKO from non-Gal antibody-mediated injury, based on the model that a more protected liver would be expected to have better function. However, antibody-mediated injury is not the only issue affecting liver xenografts. Inflammation, complement activation, and excessive coagulation limit xenograft survival. The 6-gene group had four additional genetic modifications targeting these processes which likely accounted for their longer survival. Thus, it seems that regulation of complement and coagulation pathways had a stronger influence on liver survival, while protection from immune injury contributed to more robust albumin synthesis.
Within each genotype group, there were differences in the drug regimens given. While more livers in the 3-gene and 6-gene groups received the full cocktail of additional pharmacologic interventions, these were added mainly to target platelet activation and sequestration (BIA, aGPIb, DDAVP) phenomena seen in liver xenotransplant models. Based on their mechanisms of action, these therapies are not expected to have a direct effect on albumin production.
Both AST and ALT levels remained within normal ranges in the 6-gene group. However, the 2-gene and 3-gene groups showed normal ALT levels (when controlling for one experiment) but notably elevated AST levels. This disproportionate rise in AST compared to ALT has been noted before. 14 The reason for this is unknown but could be due in part to elevated levels of hemolysis in the 2-gene and 3-gene groups.
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The elevated AST levels raise concern for hepatocyte injury, and the possibility that the albumin levels measured reflect release from ruptured cells rather than true albumin production. We feel this is unlikely because albumin is released into the portal circulation as soon as it is manufactured rather than stored in the liver, 15 and based on labeling studies in humans, albumin secretion time is short, at about 40 minutes. 16 Finally, albumin is synthesized on bound, as opposed to cytoplasmic, ribosomes making it improbable that there is a significant amount free in the cytoplasm of cells. 17 While albumin is a ubiquitous protein made in large amounts by the liver, it is certainly not the only marker of synthetic function necessary to assess in liver xenografts. Consumptive coagulopathy and thrombocytopenia have accounted for early failure of in vivo pig to baboon liver xenotransplantation models. 18, 19 Recently, prolonged survival has been achieved with human coagulation factor supplementation pointing to deficiencies of liver xenograft production or function. 3, 20 Assessment of coagulation factor levels is an important next step in our model.
As important as detecting protein production by the liver xenograft is, we also recognize that ultimately these proteins must themselves be functional. In vitro work by Zhang et al 21 showed that plasma from banna minipig inbreds was capable of activating both the extrinsic and intrinsic coagulation pathways when added to factor-deficient human plasma. These results are encouraging that porcine-produced proteins would be able to work in both in vivo large animal models and ex vivo pig-to-human models such as ours.
